Capricor Therapeutics (CAPR) Q2 2024 earnings summary

Executive summary

• Significant progress toward BLA submission for deramiocel (CAP-1002) targeting Duchenne muscular dystrophy (DMD), with strong clinical data, positive pre-BLA FDA meetings, and top-line HOPE-3 data expected in Q4 2024.

• Exosome platform (StealthX) advancing preclinically, with a COVID-19 vaccine candidate selected for Project NextGen and a Phase 1 trial planned with NIAID.

• Cash, cash equivalents, and marketable securities totaled $29.5 million as of June 30, 2024, expected to fund operations into Q1 2025.

• No products are approved for sale; revenue is from development and distribution agreements, not commercial sales.

• Active late-stage discussions for ex-U.S. partnerships, particularly in Europe, to support balance sheet and global expansion.

Financial highlights

• Q2 2024 revenue was $4 million, up slightly from $3.9 million in Q2 2023, primarily from the Nippon Shinyaku agreement.

• Net loss for Q2 2024 was $11 million ($0.35/share), compared to $7.4 million ($0.29/share) in Q2 2023; first half 2024 net loss was $20.8 million versus $15.1 million in the prior year period.

• Operating expenses rose to $15.6 million in Q2 2024 from $11.7 million in Q2 2023, driven by higher R&D, manufacturing, and stock-based compensation.

• Cash used in operating activities was $13.6 million for H1 2024, compared to $5.2 million in the prior year period.

• Cash runway expected to support operations into Q1 2025, excluding potential milestone payments.

Outlook and guidance

• Rolling BLA submission for deramiocel to start within 60 days; top-line HOPE-3 data expected in Q4 2024.

• Ex-U.S. partnership deals targeted for closure by year-end 2024 to strengthen the balance sheet.

• Ongoing preparations for commercial launch, including manufacturing scale-up and market access planning.

• Exosome vaccine candidate delivery to NIAID planned for late 2024, with Phase 1 trial initiation targeted for late 2024 or early 2025.

• Further guidance on pivotal milestones to be provided after pre-BLA meeting details are finalized.